Mazdutide

Product Name: Mazdutide

CAS No: 2259884-03-0

Purity: 95%

Molar Mass: 4563.06

Chemical Formula: C210H322N46O67

Synonyms: IBI-362, LY-3305677

Storage: Store at -20℃

Target: GLP-1 RA

Application: Mazdutide (CAS: 2259884-03-0) is a peptide-based drug under investigation for its potential therapeutic applications in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. It is designed to target specific receptors or pathways involved in the regulation of intestinal inflammation and immune responses. Mazdutide functions by modulating the activity of certain immune cells and cytokines within the gut, aiming to reduce inflammation and promote mucosal healing. In pharmaceutical research, mazdutide represents a novel approach to treating IBD, offering the potential to address the underlying pathology of the disease and improve patient outcomes. Clinical trials are underway to evaluate its safety, efficacy, and therapeutic potential in patients with IBD, with the goal of providing new treatment options for individuals affected by these chronic and debilitating conditions.

Reference:

Zhang, B., Cheng, Z., Chen, J., Zhang, X., Liu, D., Jiang, H., … & Yang, W. (2024). Efficacy and safety of mazdutide in chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care, 47(1), 160-168.

Ji, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., … & Qian, L. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine, 54.